trial · primary record
Ifinatamab deruxtecan
Esophageal Squamous Cell Carcinoma
| Phase | Phase 3 |
|---|---|
| Status | RECRUITING |
| Sponsor | Unknown |
| Enrolment | 510 |
| Primary completion | 2029-11-01 |
| Primary endpoint | Overall Survival (OS) |
| Registry ID | NCT06644781 |
Provenance
- Source: ClinicalTrials.gov
- Fetched at: 2026-10-28T03:27:17.739Z
- Licence class: attribution-required
- Verdict: primary-source
- Entity id: NCT06644781
This record is rendered from the AEaH spine. If the source is unreachable the page is not generated.